A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : scu-PA / single-chain urokinase-type plasminogen activator

[Related PubMed/MEDLINE]
Total Number of Papers: 128
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   scu-PA  (>> Co-occurring Abbreviation)
Long Form:   single-chain urokinase-type plasminogen activator
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A Novel Marine Pyran-Isoindolone Compound Enhances Fibrin Lysis Mediated by Single-Chain Urokinase-Type Plasminogen Activator. FGFC1
2022 Platelet-targeted thrombolysis for treatment of acute ischemic stroke. BBB, ICH, MCAO, tPA
2021 Bioinspired In Vitro Brain Vasculature Model for Nanomedicine Testing Based on Decellularized Spinach Leaves. ---
2020 Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury. ISALI, PA, PFC, tPA
2018 Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury. ISALI, sctPA
2014 Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. ---
2012 Factor seven activating protease (FSAP): does it activate factor VII? FSAP, FVII
2011 Direct chromogenic substrate immuno-capture activity assay for testing of factor VII-activating protease. CI, FSAP, FSAP, MRI, SNP
2010 Activation of single-chain urokinase-type plasminogen activator by platelet-associated plasminogen: a mechanism for stimulation of fibrinolysis by platelets. uPA
10  2010 The cyclopentapeptide plactin enhances cellular binding and autoactivation of the serine protease plasma hyaluronan-binding protein. PHBP
11  2009 Effect of recombinant single-chain urokinase-type plasminogen activator on experimental pulmonary embolism. CO, mPAP, PTE, rt-PA
12  2009 Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits. alphaM, PFs, TCN
13  2009 Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. RBC, suPAR
14  2008 Factor VII-activating protease in patients with acute deep venous thrombosis. CRP, DVT, FSAP, FVII, FVIIa
15  2007 Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. I/R, LMW
16  2007 Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis. ---
17  2005 Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system. EC, hr-sMTf, LRP, uPA, uPAR
18  2005 Thrombolytic agents. SAK, tPA
19  2004 High-level scu-PA production by butyrate-treated serum-free culture of recombinant CHO cell line. ---
20  2004 Novel human plasma proteins, IHRP (acute phase protein) and PHBP (serine protease), which bind to glycosaminoglycans. ECM, ITI, MMPs, PHBP
21  2003 Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator. ---
22  2003 The kringle stabilizes urokinase binding to the urokinase receptor. ATF, GFD, HBS, suPAR, WT
23  2002 Effects of inhaled plasminogen activator on the balance between coagulation and fibrinolysis in traumatized pigs. ---
24  2002 Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension. PPH
25  2002 [Characterization of urokinase type plasminogen activator modified by phenylglyoxal]. ---
26  2002 [Single-chain urokinase-type plasminogen activator (scu-PA) purification by immuno-affinity chromatography]. KLH
27  2001 Basic principles in thrombolysis: regulatory role of plasminogen. TAFI
28  2001 Coronary artero-venous gradient of endogenous urokinase. tcu-PA, uPA
29  2001 Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3). APMA
30  2001 Identification of the epidermal growth factor-like domains of thrombomodulin essential for the acceleration of thrombin-mediated inactivation of single-chain urokinase-type plasminogen activator. EGF, TM
31  2001 Jet and ultrasonic nebulization of single chain urokinase plasminogen activator (scu-PA). ARDS, MMD
32  2000 Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system. EACA, uPA
33  2000 The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells. HUVEC, uPA
34  1999 Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment. NTF, uPAR
35  1999 Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects. DIC
36  1999 Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. AMI, AUC, BASE, HMW
37  1999 Two distinct urokinase-serpin interactions regulate the initiation of cell surface-associated plasminogen activation. PAI-3, tcu-PA, uPAR
38  1998 Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. suPAR
39  1998 Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo. SMC, uPAR
40  1998 Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). uPAR
41  1998 The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin. ATIII
42  1997 Relationship between preinfarction angina and time interval to reperfusion with thrombolytic therapy in acute myocardial infarction. CK, LVEDVI, LVEF, MI, TIMI
43  1996 A sensitive bioimmunoassay for thrombin-cleaved two-chain urokinase-type plasminogen activator in human body fluids. BIA
44  1996 Characterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structure. ---
45  1996 Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. rscuPA, rt-PA
46  1996 Interference of an activity assay of tissue-type plasminogen activator in human plasma by endogenous factors. PAI-1, tPA
47  1996 Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? ACT, CPB, TAT
48  1996 Secretory production of recombinant urokinase-type plasminogen activator-annexin V chimeras in Pichia pastoris. aa, AOX1, IU, MPR, PL
49  1995 A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group. ---
50  1995 Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase. ---
51  1995 Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas. ATF, uPA
52  1995 Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. PSA, uPA
53  1995 Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass. CPB, tcu-PA
54  1994 Activation of thrombin-inactivated single-chain urokinase-type plasminogen activator by dipeptidyl peptidase I (cathepsin C). ---
55  1994 Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase. GPI, tcu
56  1994 Design and evaluation of a thrombin-activable plasminogen activator. ---
57  1994 [Development of new thrombolytic substances]. r-PA
58  1994 [Pro-urokinase for infarct therapy]. tcu-PA
59  1993 Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator. HMW, LMW
60  1993 Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction. tPA
61  1993 Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. ---
62  1993 Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator. NGF-gamma, PAGE
63  1993 Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. tPA
64  1993 Regulation of scu-PA secretion and u-PA receptor expression in osteoblast-like cells. cAMP, dbcAMP, PKC, PMA
65  1993 Role of the glycosaminoglycan component of thrombomodulin in its acceleration of the inactivation of single-chain urokinase-type plasminogen activator by thrombin. TM
66  1993 The tissue plasminogen activator finger domain confers fibrin-dependent enhancement of catalytic activity to single-chain urokinase-type plasminogen activator. tPA
67  1993 Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). rt-PA, tPA
68  1992 Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator. rscu-PA
69  1992 Comparison of the effects of fibrin binding on the biochemical properties of single-chain tissue-type plasminogen activator (t-PA) and single-chain chimeric plasminogen activator (t-PA/scu-PA). sct-PA, tPA
70  1992 Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation. EC
71  1992 In vivo and in vitro interaction of high and low molecular weight single-chain urokinase-type plasminogen activator with rat liver cells. ---
72  1992 K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man. tPA
73  1992 Kinetics of plasmin activation of single chain urinary-type plasminogen activator (scu-PA) and demonstration of a high affinity interaction between scu-PA and plasminogen. ---
74  1992 The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made. tPA
75  1992 The rationale of prevention of thrombosis by enhancing blood levels of single-chain urokinase-type plasminogen activator (scuPA). ---
76  1992 Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits. HPAs, tPA
77  1992 Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. ---
78  1992 Thrombomodulin is a cofactor for thrombin degradation of recombinant single-chain urokinase plasminogen activator "in vitro" and in a perfused rabbit heart model. EGF
79  1991 Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin. ---
80  1991 An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein. DEF, scuPA-AA
81  1991 Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model. rscu-PA, rt-PA, tPA
82  1991 Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction. rt-PA
83  1991 Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. AMI, tcu-PA
84  1991 Hybrid molecules: insights into plasminogen activator function. tPA
85  1991 Importance of plasminogen activator inhibitor type 1 (PAI-1) for preventing single chain urokinase plasminogen activator (scu-PA) conversion into two chain urokinase plasminogen activator (tcu-PA) in plasma in vitro. PAI-1, tcu-PA
86  1991 Monoclonal antibodies monospecific to single-chain urokinase-type plasminogen activator (scu-PA). mAbs, UK
87  1991 Mutations affecting the activity of urokinase-type plasminogen activator. ---
88  1991 Optimization of pro-urokinase secretion from recombinant Saccharomyces cerevisiae. RQ
89  1991 Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. dansyl-EGRck, DFP
90  1990 Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator. ---
91  1990 Interventions in acute myocardial infarction. APSAC or anistreplase, MI, tPA
92  1990 Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction. rt-PA
93  1990 Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu). rtcu-PA
94  1989 Assay method for single-chain urokinase-type plasminogen activator. ---
95  1989 Comparison of thrombolytic agents: selected hematologic, vascular and clinical events. APSAC, rt-PA, SK, UK
96  1989 Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody. ---
97  1989 Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis. rt-PA
98  1989 [Plasminogen activators as thrombolytic agents in myocardial infarction]. APSAC, tPA
99  1988 A sequence-dependent monoclonal antibody specific for single-chain urokinase. Acm
100  1988 Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. tPA